Welcome to the e-CCO Library!

P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McCartney S.*1, Lindsay J.2, Russell R.3, Gaya D.3, Shaw I.4, Murray C.5, Finney-Hayward T.6, Sebastian S.7

Created: Wednesday, 20 February 2019, 10:36 AM
P363: The minimal invasive surgery in combination with negative pressure wound therapy for perianal fistulas in Crohn’s colitis lead to the fast introduction of the biological treatment and improve the results
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Banasiewicz*1, J. Paszkowski1, J. Hermann1, J. Cwalinski1, P. Eder2, K. Stawczyk-Eder2, K. Waszak2, A. Dobrowolska2

Created: Friday, 22 February 2019, 9:41 AM
P364 New insights into the molecular mechanisms of thalidomide in paediatric inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Lucafò1, M. Bramuzzo2, L. Pugnetti3, M. Gerdol4, S. Greco4, M. Paci5, D. Curci6, M. Nonnis4, S. Renzo5, P. Lionetti5, A. Tommasini1, G. Decorti7, G. Stocco4

Created: Thursday, 30 January 2020, 10:12 AM
P364: A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Eriksson C.1, Rundquist S.*2, Lykiardopoulos B.3, Karlén P.4, Grip O.5, Söderman C.6, Almer S.7, Hertervig E.8, Gunnarsson J.9, Delin J.10, Strid H.11, Sjöberg M.12, Öberg D.13, Hjortswang H.3, Halfvarson J.14 The SWIBREG SVEAH Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P364: Comparison of two treatment strategies in IBD: Biosimilar adalimumab (CinnoRA®) in monotherapy and in combination with azathioprine
Year: 2022
Source: ECCO'22
Authors: Alborzi Avanaki, F.(1);Moghbel, N.(2);Aletaha, N.(3);E.Daryani, N.(4);Farahvash, M.J.(5);Miroliaii, A.(6);Shayegan, N.(6);Anjidani, N.(7);
Created: Friday, 11 February 2022, 3:52 PM
P364: Patient reported outcomes, partial MAYO score and SCCAI are equally accurate in predicting mucosal healing in UC: final results form a prospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Golovics, P.(1);Gonczi, L.(2);Reinglass, J.(3);Verdon, C.(3);Pundir, S.(3);Afif, W.(3);Wild, G.(3);Bitton, A.(3);Bessissow, T.(3);Lakatos, P.L.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P364: Presence of malnutrition adversely affects short-term clinical outcomes in a sample of patients with Crohn's disease (CD)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Karachaliou, A.(1)*;Lekakis, V.(2);Bletsa, M.(3);Mantzaris, G.J.(4);Tzouvala, M.(5);Bamias, G.(6);Kontogianni, M.D.(1);
Created: Friday, 14 July 2023, 11:05 AM
P364: Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Iborra1*, J. Herreras2, M. Boscá-Watts3, X. Cortés4, G. Trejo3, B. Beltran1, E. Cerrillo1, M. Minguez3, P. Nos1

Created: Thursday, 21 February 2019, 9:14 AM
P364: The value of faecal calprotectin for assessing endoscopic activity and predicting future clinical course in patients with active ulcerative colitis treated with granulomonocytapheresis: a prospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Shimoyama*1, T. Yamamoto1, S. Umegae1, K. Matsumoto1

Created: Friday, 22 February 2019, 9:41 AM
P365 Identification of predictive factors of AZA/6-MP treatment outcome in paediatric luminal Crohn’s disease: a multicentre study of the paediatric IBD Porto group of ESPGHAN
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. LERCHOVA1, O. Hradsky1, M. Kulich2, G. Veres3, J.A. Dias4, M. Sladek5, S. Kolacek6, S. Van Biervliet7, J. Melek8, D. Serban9, K. Winther10, T. de Meij11, J. Schwarz12, K.L. Kolho13, J.C. Escher14, J. Bronsky1

Created: Thursday, 30 January 2020, 10:12 AM
P365: Autologous haematopoietic stem cell transplantation in refractory Crohn’s disease: experience of a Brazilian tertiary centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Oba*1,2, F. Steinwurz2, A. Scanavini Neto3, O. Ambrogini4, C. Silva5, S. Nakashima5, M. Santos5, N. Hamerschlak6

Created: Friday, 22 February 2019, 9:41 AM
P365: Biological interventions for induction and maintenance of mucosal healing in Crohn’s disease: A Cochrane systematic review
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Ricciuto1*, P. Church1, M.J. Stewart2, H.H. Shim2, M. Storr3,4, R. Panaccione2, A. Griffiths1, C. Seow2

Created: Thursday, 21 February 2019, 9:14 AM
P365: Correlation between patient-reported outcomes (PROs) and patient-reported disease activity in Ulcerative Colitis (UC): Findings from the ICONIC study
Year: 2021
Source: ECCO'21 Virtual
Authors: Ghosh, S.(1);Casellas, F.(2);Kligys, K.(3);Sanchez Gonzalez, Y.(4);Peyrin-Biroulet, L.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P365: Psoriasis in Inflammatory Bowel Disease: Comparison of Extraintestinal Manifestations and Effect of Anti-TNF Therapies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kilic, D.T.(1);Yuksel, I.(1,2)*;
Created: Friday, 14 July 2023, 11:05 AM
P365: Real-world effectiveness of adalimumab in patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Armuzzi*1, C. Taxonera2, J. Panes3, P. Lakatos4, N. Fisseha5, B. Pappalardo5

Created: Friday, 22 February 2019, 9:49 AM
P365: Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Aguas M.*1,2, Bosό V.3, Navarro B.1, Marqués-Miñana M.R.3, Bastida G.1,2, Beltrán B.1,2, Iborra M.1,2, Monte-Boquet E.3, Poveda-Andrés J.L.3, Nos P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P365: Weight gain after initiation of adalimumab in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Darwin, L.(1);Wall, C.(2);Su, H.(1);Gearry, R.B.(2);
Created: Friday, 11 February 2022, 3:52 PM
P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.C. Dubinsky1, D.P. Hudesman2, F. Steinwurz3, N. Kulisek4, L. Salese4, J. Paulissen5, C. Su4, D. Ponce de Leon6, F. Magro7

Created: Thursday, 30 January 2020, 10:12 AM
P366: A service evaluation of pre-operative nutritional optimisation in patients with Crohn’s disease using exclusive enteral nutrition with or without supplementary parenteral nutrition
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. O'Hanlon1, A. Sandall1,2, A. Darakhshan3, A. Williams3, E. Westcott3, K. Patel4, P. Irving4, M. Lomer1,2

Created: Friday, 22 February 2019, 9:41 AM